Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Nashville news?

Get a daily digest of the most important stories affecting your hometown with the Axios Nashville newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Columbus news?

Get a daily digest of the most important stories affecting your hometown with the Axios Columbus newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Dallas news?

Get a daily digest of the most important stories affecting your hometown with the Axios Dallas newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Illustration: Megan Robinson/Axios

Generic drug companies have asked Pfizer, Moderna and Johnson & Johnson to license their COVID-19 vaccine technology to help increase global production, but so far the vaccine makers have given them the cold shoulder.

Why it matters: Other companies are saying they have extra capacity to make more vaccines. Not using that extra capacity could prolong the pandemic throughout the world.

What they're saying: "Right now our biggest problem is that we cannot produce enough vaccine to meet the high demand," Moderna CEO Stéphane Bancel told a Swiss newspaper this week.

Behind the scenes: Several generics manufacturers have reached out to Pfizer, Moderna and Johnson & Johnson, and "none of their offers have been met positively," said one industry source, who asked not to be named to talk about private discussions.

  • Teva's CEO told the Financial Times the company "made it clear that we were willing to help, but it has not resulted in any agreements."
  • The Biden administration also has been unsuccessful in arranging licensing deals, and has only obtained extra doses from Pfizer to donate, according to the New York Times.

Between the lines: Generic drug companies already produce vaccines for other parts of the world, and they are saying they could help out now that raw material shortages are less of a concern.

  • A Pfizer spokesperson said the company and its vaccine partner BioNTech "select contract manufacturers using a rigorous process based on several factors" like quality, safety, capacity and highly trained workers. They continue to "pursue opportunities to bring new partners into its supply chain network."
  • Moderna and J&J did not immediately respond to questions.

Flashback: "In certain instances, such as public health emergencies, trade partners may legally issue a compulsory license," the drug industry's lobbying group PhRMA wrote in a 2017 blog. It also noted that "studies have actually proven that compulsory licensing is an ineffective and unsustainable tactic."

Correction: This story has been corrected to note that PhRMA does not support compulsory licensing. Previously, the article stated that generic drug companies making vaccines during a pandemic, without the patent owner's permission, is something the drug industry would have supported four years ago.

Go deeper

DeSantis to convene state legislature to fight COVID vaccine mandates

Photo: Paul Hennessy/SOPA Images/LightRocket via Getty Images

Florida Gov. Ron DeSantis announced Thursday that he will convene a special session of the state legislature to combat coronavirus vaccine mandates enacted by businesses and "provide protections for employees."

Why it matters: This is the Republican governor's latest move to penalize local entities that implement mask or vaccine mandates to contain the spread of the virus.

9 hours ago - Health

The world is on track with COVID vaccines — except for poor countries

Expand chart
Data: KFF; Chart: Will Chase/Axios

The world as a whole is on track to meet the WHO's goal of 70% of the global population vaccinated by mid-2022. But low-income countries are very much not, according to a new KFF analysis.

Why it matters: Without some kind of intervention, people who live in low-income countries will keep dying long into the future as the virus keeps circulating, and the risk of dangerous new variants will rise.

Tina Reed, author of Vitals
9 hours ago - Health

Experts predict an easier COVID winter this year

Illustration: Annelise Capossela/Axios

This winter probably won't bring another crushing COVID wave, experts say.

Why it matters: Last winter was the deadliest phase of the pandemic, and many Americans are braced for cold weather to once again usher in a surge in cases and deaths. But there are good reasons to think this year won't be nearly as bad.